PharmaCyte Biotech, Inc. provided earnings guidance for Fiscal Year 2022. Net loss for fiscal year 2022 is expected to be approximately $4.2 million or approximately $0.27 per share, compared with a net loss of $3.6 million, or $2.45 per share, for the prior fiscal year.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.96 USD | -2.97% | -8.41% | -9.26% |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-9.26% | 16.57M | |
+40.73% | 739B | |
+32.83% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+15.00% | 240B | |
+9.78% | 210B | |
-5.52% | 206B | |
+6.17% | 164B |
- Stock Market
- Equities
- PMCB Stock
- News PharmaCyte Biotech, Inc.
- PharmaCyte Biotech, Inc. Provides Earnings Guidance for Fiscal Year 2022